Analysts see no lift for downbeat cannabis stocks from Chuck Schumer's bill

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 23 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 97%

Россия Новости Новости

Россия Последние новости,Россия Последние новости

An ambitious and long-awaited cannabis bill from Senate Majority Leader Chuck Schumer is unlikely to pass and will not likely stoke interest in U.S. cannabis stocks, analysts say.

While the formal introduction of the Cannabis Administration and Opportunity Act this week has drawn some praise, it landed with a thud on Wall Street.

He reiterated a buy rating on WM Technology MAPS, -5.83% and hold ratings on GrowGeneration Corp. GRWG, -5.74%, Hydrofarm Holdings HYFM, -4.87% and Scotts Miracle-Gro SMG, -3.43% as beneficiaries of the current environment. Jefferies analyst Owen Bennett said the CAOA reflects growing momentum behind cannabis reform and its introduction now should give Congress more time to switch to a more “passable” measure by the end of the year.

 

Спасибо за ваш комментарий. Ваш комментарий будет опубликован после проверки

Look at Jazz Pharma stock historical performance since 2007 IPO. Remember that Jazz Pharma acquired GW Pharma (the leading medical cannabis pharmaceutical products manufacturer) in May 2021. Democrats seem unable to make decisions to help the US economy recover and grow.

Weed…. It’s not as good as everyone makes it out to be.

Exact O P P O S I T E is gonna happen and it's about to be G N A R L Y 🪴 🌱 🌿 🌾 🌵 🏵 🪴 🌱 🌿 🌾

Big pharma has wayyyyy to much to lose and so do the jails.

Мы обобщили эту новость, чтобы вы могли ее быстро прочитать.Если новость вам интересна, вы можете прочитать полный текст здесь Прочитайте больше:

 /  🏆 3. in RU

Россия Последние новости, Россия Последние новости